|
18F-DCFpyL Clinical Trials
6 actively recruiting trials across 4 locations
Also known as: PSMA, PET, [F18]-Piflufolastat, Pylarify, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}ureido)-pentanedioic acid
Pipeline
Early 1: 1Phase 2: 3Phase 4: 1
Top Sponsors
- National Cancer Institute (NCI)3
- University of Wisconsin, Madison1
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
- Brigham and Women's Hospital1
Indications
- Cancer6
- Prostate Cancer4
- Biochemically Recurrent1
- Metastatic Castration-Resistant Prostate Carcinoma1
- Metastatic Castration-resistant Prostate Cancer1
Bethesda, Maryland3 trials
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
National Institutes of Health Clinical Center
Phase 2
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center
Phase 2
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
National Institutes of Health Clinical Center
Baltimore, Maryland1 trial
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
SKCCC at Johns Hopkins
Early 1
Boston, Massachusetts1 trial
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Dana Farber Cancer Institute
Phase 4
Madison, Wisconsin1 trial
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin School of Medicine and Public Health
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.